Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight
What Doximity (NYSE: DOCS) CFO resignation means for governance, capital allocation, and investor confidence
Read More Pharma Industry News Vyepti and Rexulti power Lundbeck (CPH: LUN) to raise 2025 guidance after 22% adjusted EBITDA surge Lundbeck lifts 2025 guidance as Vyepti and Rexulti drive 22% EBITDA growth. Explore the neuroscience-focused strategy powering its latest earnings surge. bySrinathNovember 12, 2025